Patent Application
20200080979
The presently disclosed subject matter relates to methods and devices for detecting the presence or concentration of phase transfer catalysts (PTCs) in samples. In some embodiments, the methods and devices can be used to detect the concentration of residual PTC in a radiotracer or a radiopharmaceutical.
In the manufacture of fluorine-18 (18F)-labeled radiotracers and radiopharmaceuticals using medical cyclotron produced 18F, a phase transfer catalyst (PTC), such as the cryptand KRYPTOFIX™-222, (Merck KGAA, Darmstadt, Germany), i.e., 4,7,13,16,21,24-dexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (also known as K-222 or cryptand 222); or tetrabutylammonium hydrogen carbonate (TBAHC) can be used to complex the cation of 18F-potassium fluoride so that it can be dissolved in an organic reaction solvent. During the radio-synthesis, the radiotracer or radiopharmaceutical product is purified and formulated into the final dose.
Although the purification process is designed to remove impurities in the final dose, residual PTC is often present. As a quality control (QC) measure, a thin layer chromatography (TLC) spot is compared to a known PTC standard solution of 50 parts-per-million (ppm). In the spot test, the standard and the radiotracer or radiopharmaceutical preparation are both spotted adjacently onto a silica or alumina TLC plate, and then a stain (e.g., iodine or iodoplatinate) is applied to visualize the spots. For the radiotracer/radiopharmaceutical dose to pass this QC test, its intensity should be equal to or less than the standard. This subjective, semi-quantitative test is the current standard for residual PTC testing for K-222.
Although the crown ether 18-crown-6 can be superior to K-222 as a PTC for radiolabeling reactions by providing higher radiochemical yields, there is no currently accepted QC test for this more toxic compound in radiotracers and radiopharmaceuticals. Because of these factors, it is not currently utilized in clinical radiochemistry.
Accordingly, there is an ongoing need for additional methods and devices for determining residual PTC in radiotracer/radiopharmaceutical doses. In particular, there is an ongoing need for methods that can be applied to a broad range of PTCs, that are inexpensive and easy to use, and that provide a more accurate, non-subjective measure of residual PTC concentration, particularly at lower concentrations (e.g., less than 50 ppm).
In some embodiments, the presently disclosed subject matter provides a method of detecting the presence or concentration of a phase transfer catalyst (PTC) in a sample, the method comprising: (a) mixing a sample containing or suspected of containing a PTC with an aqueous solution comprising a potassium and/or sodium salt to provide an aqueous mixture; (b) adding an organic solvent to the aqueous mixture to provide a biphasic mixture comprising an aqueous phase and an organic phase; (c) mixing the biphasic mixture for a period of time; (d) separating the organic phase from the aqueous phase; and (e) analyzing the organic phase, thereby determining the presence or concentration of the PTC. In some embodiments, the sample containing or suspected of containing a PTC comprises a radiopharmaceutical.
In some embodiments, the radiopharmaceutical comprises fluorine-18 (18F). In some embodiments, the radiopharmaceutical is selected from the group comprising [18F]2-fluoro-2-deoxy-D-glucose (FDG) [18F]sodium fluoride; [18F]3′-deoxy-3′-fluorothymidine (FLT), [18F]fluoromisonidazole, [18F]florbetaben, [18F]florbetapir, [18F]fluoro-ethyl-tyrosine (FET), [18F]flutemetamol, [18F]-fluorocholine (FCH), [18F]fluoroethylcholine (FECH), [18F]fallypride, and [18F]6-fluor-L-2,3-dihydroxyphenylalanine (FDOPA).
In some embodiments, the PTC is selected from a quaternary ammonium salt, a cryptand, and a crown ether. In some embodiments, the PTC is selected from the group comprising K-222, tetrabutylammonium hydrogen carbonate, and 18-crown-6. In some embodiments, the organic solvent is dichloromethane. In some embodiments, step (c) comprises vortexing the biphasic mixture for about 30 seconds.
In some embodiments, the potassium and/or sodium salt is the potassium or sodium salt of a chromophoric anion. In some embodiments, the potassium and/or sodium salt is selected from the group comprising potassium permanganate and sodium resazurin.
In some embodiments, step (e) comprises measuring the light absorbance of the organic phase at one or more wavelengths of interest and comparing the light absorbance of the organic phase to the light absorbance of one or more standard solutions, wherein each of the one or more standard solutions comprises a known concentration of a complex of the PTC and the salt dissolved in the organic solvent. In some embodiments, the potassium and/or sodium salt is selected from the group comprising potassium permanganate and sodium resazurin, and the one or more wavelengths of interest is 532 nanometers (nm). In some embodiments, the aqueous solution comprising the potassium and/or sodium salt comprises about 0.1 and about 0.5 molar (M) potassium permanganate, optionally wherein the aqueous solution comprising the potassium and/or sodium salt comprises about 0.2 M potassium permanganate.
In some embodiments, the measuring is performed using a spectrophotometric device comprising a green laser and a light detector. In some embodiments, the device further comprises one or more of a reservoir for the organic phase, a microprocessor, a solid body for holding a sample reservoir in the path of a beam of light from the green laser, and a display for displaying one or more absorbance measurement values.
In some embodiments, step (e) comprises measuring the electrical conductivity of the organic phase and comparing the electrical conductivity of the organic phase to the electrical conductivity of one or more standard solutions, wherein each of the one or more standard solutions comprises a known concentration of a complex of the PTC and the salt dissolved in the organic solvent. In some embodiments, the potassium and/or sodium salt comprises a mixture of sodium resazurin and potassium carbonate. In some embodiments, the aqueous solution comprising the potassium or sodium salt comprises between about 0.02 and about 0.06 molar (M) sodium resazurin and between about 0.02 and about 0.06 M potassium carbonate. In some embodiments, the aqueous solution comprises equimolar concentrations of the sodium resazurin and the potassium carbonate, optionally wherein both the sodium resazurin and the potassium carbonate have a concentration of about 0.05 M. In some embodiments, the measuring is performed with a photodiode resistor or a multimeter.
In some embodiments, the sample has a volume of between about 50 microliters (μL) and about 100 μL, and the aqueous solution comprising a potassium and/or sodium salt has a volume of about 50 μL. In some embodiments, adding an organic solvent comprises adding about 1 milliliter (mL) of the organic solvent.
In some embodiments, the potassium and/or sodium salt is the potassium or sodium salt of a chromophoric anion and step (e) comprises visually comparing the color of the organic phase to the color of one or more standard solutions, wherein each of the one or more standard solutions comprises a known concentration of a complex of the PTC and the salt dissolved in the organic solvent.
In some embodiments, the presently disclosed subject matter provides a method of conducting a quality control test on a radiopharmaceutical, wherein the method comprises: (a) mixing an aliquot of a radiopharmaceutical solution with an aqueous solution comprising a potassium and/or sodium salt to provide an aqueous mixture; (b) adding an organic solvent to the aqueous mixture to provide a biphasic mixture comprising an aqueous phase and an organic phase; (c) mixing the biphasic mixture for a period of time; (d) separating the organic phase from the aqueous phase; and (e) analyzing the organic phase, thereby determining the concentration of a residual phase transfer catalyst (PTC) in the radiopharmaceutical. In some embodiments, the analyzing comprises (i) measuring an optical absorbance of the organic phase or an electrical conductivity of the organic phase, and (ii) comparing the optical absorbance or electrical conductivity to an optical absorbance or electrical conductivity of one or more standard solutions, wherein each of the one or more standard solutions comprises a known concentration of the PTC complexed to the potassium and/or sodium salt.
In some embodiments, the residual PTC is selected from K-222, tetrabutylammonium hydrogen carbonate, and 18-crown-6. In some embodiments, the radiopharmaceutical is selected from the group comprising [18F]2-fluoro-2-deoxy-D-glucose (FDG) [18F]sodium fluoride; p deoxy-3′-fluorothymidine (FLT), [18F]fluoromisonidazole, [18F]florbetaben, [18F]florbetapir, [18F]fluoro-ethyl-tyrosine (FET), [18F]flutemetamol, [18F]-fluorocholine (FCH), [18F]fluoroethylcholine (FECH), [18F]fallypride, and [18F]6-fluor-L-2,3-dihydroxyphenylalanine (FDOPA).
Accordingly, it is an object of the presently disclosed subject matter to provide a method for detecting the presence or concentration of a PTC in a sample or of conducting a quality control test on a radiopharmaceutical.
An object of the presently disclosed subject matter having been stated hereinabove, and which is achieved in whole or in part by the presently disclosed subject matter, other objects will become evident as the description proceeds herein below.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
”s, resistance data when the PTC was K-222 is shown by circles, transmittance data when the PTC is K-222 is shown by squares, transmittance data when the PTC is tetrabutylammonium hydrogen carbonate is shown by triangles, and transmittance data when the PTC is 18-crown-6 is shown by diamonds.
The presently disclosed subject matter will now be described more fully. The presently disclosed subject matter can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein below and in the accompanying Examples. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the embodiments to those skilled in the art.
All references listed herein, including but not limited to all patents, patent applications and publications thereof, and scientific journal articles, are incorporated herein by reference in their entireties to the extent that they supplement, explain, provide a background for, or teach methodology, techniques, and/or compositions employed herein.
While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently disclosed subject matter.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the presently disclosed subject matter belongs.
Following long-standing patent law convention, the terms “a”, “an”, and “the” refer to “one or more” when used in this application, including the claims.
The term “and/or” when used in describing two or more items or conditions, refers to situations where all named items or conditions are present or applicable, or to situations wherein only one (or less than all) of the items or conditions is present or applicable.
The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” As used herein “another” can mean at least a second or more.
The term “comprising”, which is synonymous with “including,” “containing,” or “characterized by” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. “Comprising” is a term of art used in claim language which means that the named elements are essential, but other elements can be added and still form a construct within the scope of the claim.
As used herein, the phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. When the phrase “consists of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.
As used herein, the phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps, plus those that do not materially affect the basic and novel characteristic(s) of the claimed subject matter.
With respect to the terms “comprising”, “consisting of”, and “consisting essentially of”, where one of these three terms is used herein, the presently disclosed and claimed subject matter can include the use of either of the other two terms.
Unless otherwise indicated, all numbers expressing quantities of time, absorbance, transmittance, resistance, wavelength, concentration, volume and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently disclosed subject matter.
As used herein, the term “about”, when referring to a value is meant to encompass variations of in one example ±20% or ±10%, in another example ±5%, in another example ±1%, and in still another example ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods.
Numerical ranges recited herein by endpoints include all numbers and fractions subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, 4.24, and 5). Similarly, numerical ranges recited herein by endpoints include subranges subsumed within that range (e.g. 1 to 5 includes 1-1.5, 1.5-2, 2-2.75, 2.75-3, 3-3.90, 3.90-4, 4-4.24, 4.24-5, 2-5, 3-5, 1-4, and 2-4).
The term “complex” as used herein refers to an entity formed via non-covalent interactions between at least two chemical species, such as between an organic molecule and another organic molecule, salt, or an ion (e.g., a cation). In some embodiments, the complex can comprise one or more coordinate bond between a cation and an organic molecule ligand comprising an electron pair donor, ligand or chelating group. Thus, the organic molecule (which can also be referred to as a ligand or chelating group) generally comprises one or more electron pair donors, molecules or molecular ions having atoms (e.g., oxygen or nitrogen atoms) with unshared electron pairs available for donation to a cation, such as a sodium or potassium ion.
The term “coordinate bond” refers to an interaction between an electron pair donor and a coordination site on a cation resulting in an attractive force between the electron pair donor and the cation. The use of this term is not intended to be limiting, in so much as certain coordinate bonds also can be classified as have more or less covalent character (if not entirely covalent character) depending on the characteristics of the metal ion and the electron pair donor.
The term “phase transfer catalyst” (or PTC) as used herein refers to a chemical compound or species that facilitates the migration of a chemical reagent from one phase (e.g., an aqueous phase) to another phase (e.g., an organic phase). Suitable PTCs include, but are not limited to quaternary ammonium salts, crown ethers, and cryptands.
The term “quaternary ammonium salt” as used herein refers to a compound with the formula NR4+X− wherein each R is independently an alkyl or aryl group and X is an anion that can dissociate from the cation in an aqueous environment, as well as to the cation thereof (i.e., the cation with the formula NR4+). The cation can also be referred to herein as a quaternary ammonium species. In some embodiments X− is a halogen anion (e.g., chloride, bromide, or iodide), a bicarbonate (or hydrogen carbonate, i.e., HCO3), or a hydroxyl anion. Exemplary quaternary ammonium salts suitable for use as PTCs include, but are not limited to, tetrabutylammonium hydrogen carbonate, tri-n-butyl-methylammonium chloride, phenyltrimethylammonium bromide, tetra-n-butylammonium bromide, tetraethylammonium chloride, triethylbenzylammonium chloride, ethyltrimethylammonium iodide, trimethyloctodecylammonium chloride, trimethyldodecylammonium chloride, tetra-n-propylammonium chloride, methyltriocylammonium chloride, and the cations thereof.
The term “crown ether” as used herein refers to a cyclic polyether. Exemplary crown ethers include cyclic oligomers of ethylene oxide. In some embodiments, two carbon atoms of an alkylene moiety of a cyclic polyether can be replace by two carbon atoms from an aryl moiety, such as phenyl or naphthyl, which can be substituted or unsubstituted at the carbons not forming part of the backbone of the cyclic polyether. The oxygen atoms of the crown ethers can coordinatively bind to cations, thereby forming complexes with the cations or their salts. The crown ethers can act as multidentate ligands for cations. An exemplary crown ether is 18-crown-6, where 18 is the total number of atoms in the backbone of the cyclic polyether and 6 is the number of oxygen atoms in the backbone of the cyclic polyether. Additional exemplary crown ethers include, but are not limited to, 15-crown-5, benzo-15-crown-5, 12-crown-4, and dibenzo-18-crown-6.
The term “cryptand” as used herein refers to a bicyclic or polycyclic multidentate ligand for a cation or a salt thereof. An exemplary cryptand is [2,2,2]cryptand (i.e., K-222), wherein each 2 indicates a number of oxygen atoms in a polyether bridge between two nitrogen atoms. In some embodiments, the polyether bridge can include one or more arylene moiety. In some embodiments, the oxygen atoms of the polyether bridges can be replaced by nitrogen atoms.
The terms “radionuclide”, “radioactive isotope” and “radioisotope” refer to an unstable atom that has excess nuclear energy. Radionuclides lose the excess energy via a radioactive decay process (e.g., positron emission or beta decay), forming a stable nuclide or another radionuclide that can then decay to form a stable nuclide.
The term “radiotracer” refers to an imaging agent, e.g., used in medicine or in veterinary practice, that comprises a radionuclide.
The term “radiopharmaceutical” refers to a pharmaceutical compound (i.e., a compound that provides a beneficial therapeutic effect in treating a medical or veterinary disease or condition) that comprises a radionuclide.
The term “chromophoric” as used herein refers to an ionic species, organic compound, or a group within an organic compound or ionic species that absorbs light (e.g., visible light) at a particular wavelength (e.g., a particular wavelength between 400 and 700 nm) and, thus, makes the species or compound appear colored. For example, chromophoric anions based on organic compounds typically include a conjugated system of alternating double and single bonds that can provide resonance stabilization and a group that provides a negative charge (e.g., a carboxylate or sulfonate).
Crown ethers and cryptands are soluble in both aqueous and lipophilic organic solvents and are used as PTCs in chemistry. Nucleophilic fluorinations frequently employ 18-crown-6 ether as the PTC for potassium fluoride, and nucleophilic radio-fluorinations typically utilize the cryptand KRYPTOFIX™ (Merck KGAA, Darmstadt, Germany; also referred to herein as K-222) as the PTC for the production of 18F-labeled radiotracers and radiopharmaceuticals. K-222 is typically preferred in radiochemistry because instead of a 2-dimensional cation complexation, it forms a 3-dimensional complex that is 104 times more stable than the corresponding 18-crown-6/potassium cation complex. As a result of the more solvated ion pair, the fluoride reactivity is increased, which is important in no-carrier-added radiofluorinations where the [18F]fluoride is present in low nanomole quantities [1-6]. Quaternary ammonium salts, such as tetrabutylammonium hydrogen carbonate (TBAHC) and tetraethylammonium hydrogen carbonate are also PTCs used in nucleophilic fluorination chemistry [7].
During radiopharmaceutical production of 18F-labeled radiotracers and radiopharmaceuticals for clinical use, quality control (QC) spot tests are used to verify that the K-222 or tetrabutylammonium cation (TBA) is at or below the United States Pharmacopeia (USP) established limit of 50 ppm. The 50 ppm limit for K-222 and TBA has been set because these PTCs are toxic compounds. 18-Crown-6 currently has no USP limit or an accepted test, and is not employed in the production of clinical radiotracers or radiopharmaceuticals because it has higher toxicity than K-222. 18-Crown-6 has been shown to be more toxic than K-222 in animals (oral LD50 525 mg/kg vs up to 2000 mg/kg in rats); and in rabbits, doses as low as 6 mg/kg lead to neurological symptoms. Based on this data, it is presumable that an acceptable level would likely be set at around 25 ppm [8]. However, in development on the radiosynthesis of [18F]fluorocholine, the use of 18-crown-6 as the PTC instead of K-222 has been found to provide a much higher radiochemical yield of the radiotracer. Thus, a PTC QC method that allows more precise quantification and verification of low levels of 18-crown-6 in radiopharmaceuticals would likely facilitate its adoption and utilization when advantageous.
The current QC spot test consists of spotting a K-222 or TBA 50 ppm standard onto a silica thin layer chromatography plate, and then adjacently spotting the radiotracer or radiopharmaceutical formulation. Once the spots have dried, they are visualized with iodine vapor or, in the case of K-222, an iodoplatinate solution can be used instead. If the intensity of the radiotracer spot is equal to or less dark than the standard spot, the dose passes. This qualitative test is somewhat subjective, but there is currently no widely used, highly quantitative method utilized for routine PTC QC testing of radiotracers and radiopharmaceuticals [9]. Thus, it can be difficult, for example, to optimize the synthesis of radiotracers/radiopharmaceuticals to avoid higher residual PTC concentrations. In addition, K-222 spot test “false positives” are possible with radiotracers/radiopharmaceuticals containing tertiary amine functions, and “false negatives” may occur when stabilizers are added to the radiotracer/radiopharmaceutical preparation. [10].
In an effort to meet the need for an alternative analysis method for PTC testing, two analytical instrumental methods (i.e., gas chromatography and high-performance liquid chromatography) have been evaluated for measuring residual K-222 levels. A main drawback of these methodologies is the expensive equipment required [11,12]. Recently, a microfluidic “spectroscopy chip” was developed for use with a microfluidic radiosynthesis system that uses iodoplatinate as a test reagent. It allows spectrophotometric measurement of K-222 in radiopharmaceuticals with a limit of detection of 28 ppm [13]. Additionally, another spectrophotometric method has been investigated that involves measuring the absorbance of a K-222/7, 7, 8, 8-Tetracyanoquinodimethane charge transfer complex. It was found to have a working range of 0-30 ppm [14]. Currently, there is one FDA approved automated radiopharmaceutical quality-control testing platform (TRACER-QC™ by Trace-Ability, Inc., Culver City, Calif., United States of America). This machine has the capability to carry out all QC testing (including K-222 QC using an iodoplatinate-based optical limit test) for [18F]2-fluorodeoxyglucose ([18F]FDG) production, but is not in wide use because the cost of the device is prohibitively expensive for many academic and commercial radiopharmacies. This QC testing platform also has the limitation that it is not able to analyze for TBA when applied to radiotracers/radiopharmaceuticals that use this PTC.
In some embodiments, the presently disclosed subject matter provides a method for quantitively testing for the presence or concentration of a PTC in a sample suspected of, or known to contain, a PTC. In some embodiments, the sample contains PTC at a concentration of less than 150 ppm, less than 100 ppm, or less than 50 ppm. In some embodiments, the sample is a radiotracer or radiopharmaceutical dose formulation and the method can determine the concentration of residual PTC in the sample (i.e., the amount of PTC remaining after the synthesis of the PTC). Macrocyclic PTCs allow the dissolution of inorganic salts, such as potassium [18F]fluoride in organic solvents by enclosing the potassium ion in the interior of their cage-like structure, which disperses the charge of the potassium ion over a greater area, facilitating solubility in a relatively nonpolar solvent medium. In the case of organic salt PTCs, such as the quaternary ammonium salt tetrabutylammonium hydrogen carbonate, the hydrogen carbonate anion forms hydrogen bonds with the negatively charged fluoride and this negative complex is surrounded by positive tetrabutylammonium cations, allowing dispersion of the charge and dissolution. The presently disclosed methods are based on the ability of PTCs to solubilize organic salts in relatively nonpolar organic solvents as a means of quantification. Quantification methods can include visual colorimetry, spectrophotometric analysis, or measurement of electrical conductance through the organic solvent.
More particularly, in some embodiments, the presently disclosed method comprises mixing a small amount of a sample known or suspected of containing PTC (e.g., residual PTC from a radiosynthesis) with a small amount of an aqueous potassium or sodium salt solution (e.g., a potassium or sodium salt solution comprising a chromophoric ion). In some embodiments, the sample is from a radiotracer or radiopharmaceutical dose. In some embodiments, the radiotracer or radiopharmaceutical comprises a radioisotope selected from the group including, but not limited to, 18F, 11C, 13N, 15C, 32P, 67Ga, 99mTc, and 123I. In some embodiments, the radiotracer or radiopharmaceutical comprises 18F. In some embodiments, the sample comprises an aliquot from a radiopharmaceutical dose and the radiopharmaceutical is selected from the group comprising [18F]2-fluoro-2-deoxy-D-glucose (FDG) [18F]sodium fluoride; [18F]3′-deoxy-3′-fluorothymidine (FLT), [18F]fluoromisonidazole, [18F]florbetaben, [18F]florbetapir, [18F]fluoro-ethyl-tyrosine (FET), [18F]flutemetamol, [18F]-fluorocholine (FCH), [18F]fluoroethylcholine (FECH), [18F]fallypride, and [18F]6-fluor-L-2,3-dihydroxyphenylalanine (FDOPA).
In some embodiments, the small amount of the sample (e.g., the aliquot of the radiopharmaceutical or radiotracer) has a volume of between about 50 microliters (μL) and about 100 μL (e.g., 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or about 100 μL). In some embodiments, the amount of sample is about 50 μL.
The amount of the aqueous salt solution can vary depending upon the concentration of the salt solution and/or the identity of the salt in the aqueous salt solution. In some embodiments, the concentration of salt is optimized so that the volume of the aqueous salt solution is between about 0.5 and about 1 times the volume of the radiotracer or radiopharmaceutical dose amount. In some embodiments, the amount of the aqueous salt solution is about 50 μL.
In some embodiments, the aqueous salt solution comprises at least one potassium or sodium salt of a chromophoric anion. In some embodiments, the aqueous salt solution comprises potassium permanganate (KMnO4) or sodium resazurin. However, any suitable potassium or sodium salt of a chromophoric anion can be used. In some embodiments, the chromophoric anion is a carboxylate or sulfonate of an organic compound that includes a chromophoric group selected from an anthraquinone, a methine, a phthalocyanine, a nitro group, an azo group, and a triarylmethane. Thus, for example, the potassium or sodium salt can be a sodium or potassium salt of a compound known in the art for use as a dye, such as a diazo dye or an anthraquinone dye. In some embodiments, the salt is a potassium or sodium salt of resazurin or a resazurin analog, e.g., a compound wherein the hydroxyl group of the resazurin is replaced by an alkyl or aryl ether.
In some embodiments, the aqueous salt solution comprises potassium permanganate at a concentration of between about 0.05 and about 0.5 M (i.e., about 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, or about 0.50 M). In some embodiments, the concentration of the potassium permanganate is about 0.2 M.
In some embodiments, the aqueous salt solution comprises a mixture of sodium resazurin and potassium carbonate. The concentrations of the sodium resazurin and the potassium carbonate can each be between about 0.01 M and about 0.06 M. In some embodiments, the ratio of the concentrations of the sodium resazurin and the potassium carbonate can be between about 5:1 and about 1:2. In some embodiments, the ratio of the concentrations can be between about 1.2:1 and about 1:1.2. In some embodiments, the sodium resazurin and the potassium carbonate are present at the same concentration. In some embodiments, the concentration of the sodium resazurin is about 0.04 M or about 0.05 M. In some embodiments, the concentration of the potassium carbonate is about 0.04 M or about 0.05 M.
The sample and the aqueous salt solution can be mixed in any suitable container. In some embodiments, the small amount of sample (e.g., the aliquot of radiotracer/radiopharmaceutical dose) and the salt solution can be mixed in a centrifuge tube (e.g., a 1.5 mL polypropylene centrifuge tube). Then, a suitable organic solvent is added to form a biphasic mixture. The amount of organic solvent added can range from about 10 to about 20 times the volume of the small amount of sample. In some embodiments, the amount of organic solvent is between about 0.5 mL and about 1.4 mL. In some embodiments, the amount of organic solvent is about 1 mL.
Suitable organic solvents include those that are immiscible in water (e.g., aromatic solvents, such as benzene and toluene; halogenated solvents, such as dichloromethane (DCM), chloroform, carbon tetrachloride, 1,2-dichloroethane, and trichloroethylene; alkanes such as pentane, hexane, cyclohexane, and heptane; certain esters, such as ethyl acetate and butyl acetate; certain ethers, such as diisopropyl ether, diethyl ether, and methyl-t-butyl ether; and certain ketones and alcohols, such as 2-butanone and n-butanol). In some embodiments, the organic solvent should also be one that does not absorb light at the same wavelength as an absorption maximum of the chromophoric moiety of the salt of the aqueous salt solution (i.e., a “region of interest” of the chromophoric moiety via UV-Vis spectroscopy). For example, if the chromophoric moiety of the salt absorbs light at 530-570 nm (e.g., 532 nm), a suitable organic solvent would be a solvent that does not absorb at 530-570 nm (e.g., 532 nm) significantly. In some embodiments, the organic solvent is chloroform or DCM. In some embodiments, the organic solvent is DCM.
After the organic solvent is added, the biphasic mixture is mixed so that at least some of a complex formed between any PTC present in the sample and the salt from the aqueous salt solution is extracted into the organic phase. The mixing can include any suitable mixing method, e.g., stirring, shaking, sonicating, or vortexing. In some embodiments, the mixing comprises vortexing. In some embodiments, the vortexing is performed for about 30 seconds. After the mixing, the mixture is given time for the two phases to completely separate. In some embodiments, the mixture is allowed to separate for about 1 minute.
As noted above, at this point, some of a complex formed between any PTC present in the sample and the salt from the aqueous salt solution will be dissolved in the organic phase. Thus, the organic phase can be analyzed to detect the presence and/or concentration of the complex between the PTC and the salt. The amount of complex present in the organic phase will be in proportion to the amount of residual PTC present in the sample. Thus, the concentration of complex in the organic phase is indicative of the amount of residual PTC in the sample.
The organic phase can be analyzed via any suitable method. If the salt in the aqueous salt solution includes a chromophoric anion, some of the chromophoric anion will now be present in the organic phase. More particularly, the amount of the chromophoric anion in the organic phase will be generally proportional to the amount of residual PTC in the sample. Thus, for instance, analyzing the organic phase can comprise visually comparing the organic phase to a standard solution (e.g., a solution comprising a known amount of the PTC/salt complex or an organic phase extracted from a mixture of the salt and a sample comprising a known amount of the PTC) or measuring the light absorbance of the organic phase at one or more wavelengths of interest (i.e., one or more wavelengths that correspond to a wavelength absorbed by the chromophoric anion of the salt of the aqueous salt solution) and comparing the light absorbance of the organic phase to the light absorbance of one or more standard solutions, each comprising a known concentration of the complex between the PTC and the salt of the aqueous salt solution or comprising the organic phase extracted from an aqueous mixture of the salt and a known amount of the PTC. In particular, the speed and accuracy of spectrophotoscopic analysis in combination with the ready availability of simple devices for making visible spectrophotometric measurements can provide for the measurement of residual PTC in radiotracer or radiopharmaceutical dose formulations easily at the point of care (e.g., in a hospital or clinic) or synthesis (e.g., at a radiosynthesis laboratory or manufacturing site).
More particularly, the relationship between light absorption and analyte concentration can be given by Beer's Law:
A=εlc
where A is absorbance, ε is the molar attenuation coefficient (also referred to as the extinction coefficient) of the absorbing species, c is the concentration of the absorbing species in moles per liter and l is the optical path length in centimeters. The light absorption of the organic phase can be detected using a spectrophotometric device, such as a UV-Vis spectrophotometer, which can measure the intensity of light passing through a sample, which can also be referred to as transmittance, which is expressed as a percentage. Transmittance can be converted to absorbance via the formula:
A=−log(% T/100%),
where A is absorbance, and % T is % transmittance. While absorbance is generally expected to have a linear relationship to concentration, in some embodiments, equilibrium effects can affect the results.
Devices for measuring absorption, such as UV-Vis spectrophotometers, generally include at least a light source, a light detector, and a holder or reservoir for the sample being analyzed. If the light source emits light at multiple wavelengths (e.g., if the light source is a Xenon arc lamp), the device can further include a diffraction grating or prism to separate the light so that only a select wavelength reaches the sample holder. Other suitable light sources include lasers and LEDs that can emit light at select wavelengths of interest. Suitable detectors include photomultiplier tubes, photodiodes, photodiode arrays, and charge-coupled devices (CCDs). Suitable holders/reservoirs include glass or quartz cuvettes.
In an exemplary embodiment of the presently disclosed subject matter, when the aqueous salt solution comprises KMnO4 or sodium resazurin, the organic layer can be analyzed using a spectrophotometric device that can illuminate the organic layer at 532 nm. Thus, in some embodiments, the spectrophotometric device can use a green light source (e.g., a 5 milliwatt green laser or light-emitting diode (LED)) to generate the 532 nm light. However, if the aqueous salt solution comprises a salt other than KMnO4 or sodium resazurin and the chromophoric anion of the salt does not absorb green light, light of another wavelength or color can be used to illuminate the sample and the device can include another light source (e.g., a LED or a laser that emits light of a color other than green). The device can also include one or more additional components selected from the group including, but not limited to, a sample reservoir for the organic phase (e.g., a glass cuvette), a solid body for holding the sample reservoir in the path of a light beam from the green laser or other light source, a microprocessor, a power source, and a display (e.g., a computer screen or display screen) for displaying one or more absorbance measurement values. Thus, in some embodiments, the presently disclosed methods can be performed using small, inexpensive and portable spectrophotometric devices.
Alternatively, since the extracted PTC/salt complex is soluble in nonconductive organic solvents and contains an organic salt compound, it is also possible to measure the PTC concentration by electrical resistance. The presence of charged ions in a normally nonconductive organic solution provides for the solution to conduct electricity, analogous to when water (a nonconductor) becomes electrically conductive when it contains an ionic solute. Thus, in some embodiments, the presently disclosed subject matter provides a method of detecting or quantifying PTC wherein the analysis of the organic phase comprises measuring the electrical conductivity (or resistance) of the organic phase and comparing the electrical conductivity (or resistance) of the organic phase to one or more standard solutions comprising a known concentration of a complex between the PTC and the salt of the aqueous salt solution or the organic extract from an aqueous mixture comprising the salt and a known concentration of the PTC. In some embodiments, the measuring is performed with an electrical test cell. The electrical test cell can comprise a device suitable for measuring resistance, e.g., an ohmmeter, a multimeter (e.g., a digital multimeter), or a LCR meter.
In some embodiments, the presently disclosed subject matter provides a method of conducting a QC test on a radiopharmaceutical or radiotracer, wherein the method comprises: a) mixing an aliquot of a radiopharmaceutical solution with an aqueous solution comprising a potassium and/or sodium salt to provide an aqueous mixture; b) adding an organic solvent to the aqueous mixture to provide a biphasic mixture comprising an aqueous phase and an organic phase; c) mixing the biphasic mixture for a period of time; d) separating the organic phase from the aqueous phase; and e) analyzing the organic phase, thereby determining the concentration of a residual phase transfer catalyst (PTC) in the radiopharmaceutical or radiotracer. In some embodiments, the analyzing comprises (i) measuring an optical absorbance of the organic phase or an electrical conductivity of the organic phase, and (ii) comparing the optical absorbance or electrical conductivity to an optical absorbance or electrical conductivity of one or more standard solutions, wherein each of the one or more standard solutions comprises a known concentration of the PTC complexed to the potassium and/or sodium salt or an organic extract from an aqueous mixture of the potassium and/or sodium salt and a known concentration of the PTC.
In some embodiments, the residual PTC is K-222, TBAHC, or 18-crown-6. In some embodiments, the radiopharmaceutical is selected from the group consisting of [18F]2-fluoro-2-deoxy-D-glucose (FDG) [18F]sodium fluoride; [18F]3′-deoxy-3′-fluorothymidine (FLT), [18F]fluoromisonidazole, [18F]florbetaben, [18F]florbetapir, [18F]fluoro-ethyl-tyrosine (FET), [18F]flutemetamol, [18F]-fluorocholine (FCH), [18F]fluoroethylcholine (FECH), [18F]fallypride, and [18F]6-fluor-L-2,3-dihydroxyphenylalanine (FDOPA). In some embodiments, the potassium and/or sodium salt is KMnO4 or a mixture of sodium resazurin and potassium carbonate.
The following Examples have been included to provide guidance to one of ordinary skill in the art for practicing representative embodiments of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill can appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter.
A small amount (50-100 μL) of each solution of a series of simulated radiotracer dose solutions comprising known concentrations (between about 20 and 250 ppm) of K-222 was mixed with a small amount (50 μL) of a highly colored aqueous salt solution containing 0.2 M potassium permanganate in a 1.5 mL polypropylene tube. Then, dichloromethane (DCM, 1 mL) was added to the tube and the contents were mixed by vortexing for 30 seconds. The two phases were given time to separate (about 1 minute). At this point, the DCM layer contains some of a PTC-complex comprising the chromophoric potassium permanganate. The DCM layer was then analyzed on a spectrophotometric device that used a green (532 nm) five-milliwatt laser as the light source. The PTC/chromophore complex absorbed the 532 nm light, and the amount of absorbance was proportional to the amount of PTC present. As the PTC content of the simulated radiotracer dose increased, the amount of light transmitted to the light detector decreased due to increased absorption. See
Similarly, a small amount (50-100 μL) of each of a series of simulated radiotracer dose solutions comprising known concentrations of 18-crown-6 was mixed with a small amount (50 μL) of the aqueous salt solution containing 0.2 M potassium permanganate in a 1.5 mL polypropylene tube. Then, DCM (1 mL) was added to the tube and the contents were mixed by vortexing for 30 seconds. The two phases were given time to separate (about 1 minute). The DCM layer was analyzed suing a photodiode resistor. The resistance outputs are shown in
Certified American Chemical Society grade dichloromethane (DCM) and trichloromethane (chloroform), 1,4,7,10,13,16-hexaoxacyclooctadecane (18-crown-6), 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (K-222), dyes, potassium carbonate, tetrabutylammonium hydroxide solution, 1.5 mL Eppendorf centrifuge tubes, disposable micropipette tips, micropipettes, black cuvettes, a digital multimeter (Fluke 115), and solid phase extraction cartridges were purchased from Fisher Scientific (ThermoFisher Scientific, Waltham, Mass., United States of America). [18F]fluoride was obtained from PETNET Solutions (Knoxville, Tenn., United States of America).
A simple spectrophotometer similar to that shown in
Before each sample measurement, the laser output was determined and adjusted without a cuvette. Starting with the laser at room temperature (22° C.), repeated intensity measurements were taken until values reaches 145±3 arbitrary units of light intensity (the laser output decreases as the laser heats with use). During acquisition, a new light intensity value is displayed every 2 s. Each reported measurement comprises the average of four of these values (total measurement time is 8 s). This method allowed the laser output to be consistent during sample measurement. Alternatively, the laser adjustment can be made with a cuvette in place to a value of 120±3. After laser adjustment, the pre-made sample extract was promptly pipetted into the cuvette, and four transmittance values are taken (total acquisition time 8 s). The average of these four values was taken as the final measurement value. After measuring several samples, it was observed that allowing the laser to cool (e.g., at least for 12 minutes between uses for the particular laser used herein) can be beneficial.
TBAHC was made starting with 50.51 mL (50 g) of 40-wt % (1.5 M) tetrabutylammonium hydroxide by rapidly bubbling gaseous carbon dioxide through the solution with stirring for 8 hours until the conversion was complete. Stock solutions were made by dissolving 30 mg of PTC in a 100±0.08 mL volumetric flask in saline and filling to the calibration line. Serial dilutions were then made at 0, 12, 25, 50, 75, 100, and 150 ppm by adding appropriate amounts of the stock solution to 10±0.02 mL volumetric flasks and diluting to the calibration mark with saline. In the case of TBAHC, 77.1 μL of the solution was added to a 10±0.02 mL volumetric flask and diluted to the calibration mark with saline.
Sodium salt test solutions of phenolic and acid dyes were made for initial testing by reacting with a stoichiometric quantity of sodium hydroxide to produce a 0.01 M solution.
7-Hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt (resazurin) test solutions of different concentrations and ratios of resazurin to carbonate were made by dissolving varying amounts sodium resazurin and potassium carbonate in 10±0.02 mL volumetric flasks with distilled water. The flasks were vortexed for several minutes, and then filled to the calibration mark with distilled water.
The PTC sample extraction method uses 50-100 μL of the aqueous PTC solution (or radiotracer dose solution) with 50 μL of the resazurin test solution. These solutions were combined in a polypropylene 1.5 mL centrifuge tube, and 1 mL of DCM was added. The mixture was vortexed on high for 30 s, and the layers are allowed to separate. The DCM layer (800 μL) was then removed for analysis using a micropipette.
An electrical test cell similar to that shown in
[18F]Fluorocholine radiosyntheses were carried out using a Sofie-Elixys/Flex-Chem automated radiosynthesis platform (Sofie Biosciences, Culver City, Calif., United States of America) according to a published procedure, with the only deviation being the substitution of 30 mg of 8-crown-6 for K-222 [15].
Mixing the resazurin test solution with a dilute aqueous solution of PTC in DCM or chloroform resulted extraction of the blue dye into the organic layer.
Without the addition of the PTC solution, no blue coloration was observed in the organic solvent. DCM was used as the organic solvent for further measurement studies. The DCM layer extractions of the PTC standards showed that the varying dye concentrations were easily visualized colorimetrically. At 0 ppm, the aqueous dye imparts a very faint pink color to the DCM layer. The 6 ppm extraction appears identical to the 0 ppm. At 12 ppm, the DCM layer has a faint blue color. As the PTC concentration of the standard solution increased, the DCM layer became progressively darker. This was true for each of the PTCs tested. See
Transmittance measurements at 532 nm were taken of the PTC-resazurin complex extracts in DCM of K-222, 18-crown-6, and TBA using a UV-Vis spectrophotometer. Each PTC transmittance value was measured at 0, 6, 12, 25, 50, 75, 100, and 150-ppm. See
The sodium resazurin and potassium carbonate concentrations of the test solution were optimized using a UV-Vis spectrophotometer. First, sodium resazurin and equimolar potassium carbonate were tested at 0.02, 0.03, 0.04, 0.05, and 0.06 M with a 100 ppm K-222 solution. See
To serve as a useful methodology for residual PTC testing of radiopharmaceuticals, the presence of residual solvents up to the USP limit should have no significant effect on the measurement obtained. To establish whether residual solvents pose an interference problem, a 50 ppm K-222 concentration was tested that contained varying amounts of acetonitrile or ethanol. The presence of either acetonitrile (up to 400 ppm) or ethanol (up to 5000 ppm) had no effect on the transmittance values obtained. See
Calibration curves for K-222, TBA, and 18-crown-6 transmittance values were generated using the in-house built spectrophotometer prototype with values ranging from 0-150 ppm (n=3 at each concentration) with each point being the average of four sequential measurements of the same sample (as described above). See
The electrical resistance of PTC standards ranging from 0-100 ppm was measured using the simple electrical test cell described above, and calibration curves for each PTC were made (n=6 for each concentration). See
Three commercially prepared [18F]2-fluorodeoxyglucose dose samples were each analyzed for residual K-222 by visual colorimetry, spectrophotometrically, and by electrical conductance. Results are summarized below in Table 1.
The resazurin based colorimetry technique was used in the synthesis of [18F]Fluorocholine to validate the effectiveness of the washing protocol for removing 18-crown-6 from the cation exchange solid-phase-extraction cartridge used to trap the product. The published procedure, originally developed to remove the reactant N,N-dimethylaminoethanol and K-222, removed essentially all 18-crown-6 from the radiotracer dose. The DCM extract of the final [18F]Fluorocholine dose was identical to the 0 ppm standard.
Each PTC exhibited lower transmittance values with increasing PTC concentration of the sample. See
Residual PTC in three commercially produced [18F]2-fluorodeoxyglucose radiopharmaceutical doses was successfully measured using the optimized resazurin dye test solution. The testing of three separate commercially produced dose samples for K-222 confirmed the absence of residual K-222 by visual colorimetry, spectrophotometrically, and by conductance. Additionally, resazurin-based colorimetry quickly verified the absence of 18-crown-6 in [18F]fluorocholine preclinical doses.
Resazurin based visual colorimetry is significantly more quantitative than the current spot-test method. Quantitative spectrophotometric measurements were made in the 0-100 ppm range (18-crown-6) and 0-150 ppm range (K-222 or TBA). The ability to use a low cost 532 nm laser source and an inexpensive detector to obtain accurate quantification of PTC concentrations is highly amenable for development into an inexpensive QC device that can provide an automated electronic output for batch reports, or for integration into a more complex QC testing platform that will be able to analyze for any PTC. Although quantitative results are not currently required by radiopharmaceutical standards, the industry is always growing to adjust standards to improve quality control and efficiency. A more automated, quantitative platform could be used to monitor variability in residual PTC across batches to hone production conditions for more consistent products, and to potentially find flaws in production methods that lead to large inconsistencies.
Measuring electrical resistance of the PTC-resazurin complex in organic solution is also a viable PTC analysis method that allowed accurate quantification in the 0-100 ppm range (see
All references listed below, as well as all references cited in the instant disclosure, including but not limited to all patents, patent applications and publications thereof, and scientific journal articles, are incorporated herein by reference in their entireties to the extent that they supplement, explain, provide a background for, or teach methodology, techniques, and/or compositions employed herein.
It will be understood that various details of the presently disclosed subject matter may be changed without departing from the scope of the presently disclosed subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.
This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/727,837, filed Sep. 6, 2018; the disclosure of which is incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 62727837 | Sep 2018 | US |
